Shufeng Li1, Yuchen Guo2, Jie Men3, Hanlin Fu4, Ting Xu5,6. 1. Department of Health Statistics, Fenyang College of Shanxi Medical University, 032200, Fenyang, Shanxi, China. 2. Fuwai Hospital, Chinese Academy of Medical Sciences, Xicheng District 100032, Beijing, China. 3. Department of Basic Medicine, Fenyang College of Shanxi Medical University, 032200, Fenyang, Shanxi, China. 4. Department of Epidemiology and Health Statistics, XiangYa School of Public Health, Central South University, 410008, Changsha, Hunan, China. 5. Department of Health Statistics, Fenyang College of Shanxi Medical University, 032200, Fenyang, Shanxi, China. xuting0303@outlook.com. 6. Department of Physiology, Fenyang College of Shanxi Medical University, 032200, Fenyang, Shanxi, China. xuting0303@outlook.com.
Abstract
BACKGROUND: The irreversibility of cognitive impairment of Alzheimer's disease (AD) prompts that preventing or delaying the onset of AD should be a public health priority. Vitamin B supplements can lower the serum homocysteine (Hcy) level, but whether it can prevent cognitive decline or not remains unclear. We aimed to evaluate the preventive efficacy of vitamin B supplements on the cognitive decline of elderly adults. METHODS: We searched PubMed, Embase, The Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Scopus, Science Direct, PsycINFO from inception to December 1, 2019, and then updated the retrieved results on June 1, 2020. The randomized controlled trials (RCTs) which evaluated the efficacy of vitamin B in mild cognitive impairment (MCI) patients or elderly adults without cognitive impairment were selected. Standardized mean difference (SMD) or mean difference (MD) as well as their 95 % confidence interval (CI) were calculated by performing random effects models or fixed effects models. RESULTS: A total of 21 RCTs involving 7571 participants were included for meta-analysis. The forest plots showed that there is significant effect in global cognitive function (15 RCTs, SMD: 0.36; 95 % CI: 0.18 to 0.54, P < 0.01) and Hcy (11 RCTs, MD: -4.59; 95 %CI: -5.51 to -3.67, P < 0.01), but there is no effect in information processing speed (10 RCTs, SMD: 0.06; 95 % CI: -0.12 to 0.25, P = 0.49), episodic memory (15 RCTs, SMD: 0.10; 95 % CI: -0.04 to 0.25, P = 0.16), executive function (11 RCTs, SMD: -0.21; 95 % CI: -0.49 to 0.06, P = 0.13). The value of effect size and heterogeneity did not vary apparently when excluding the low-quality studies, so we could believe that the results of meta-analysis were robust. CONCLUSIONS: Vitamin B supplements might delay or maintain the cognitive decline of elderly adults. We can recommend that the vitamin B supplements should be considered as a preventive medication to MCI patients or elderly adults without cognitive impairment. More well-designed RCTs with large sample sizes were required to clarify the preventive efficacy in the future.
BACKGROUND: The irreversibility of cognitive impairment of Alzheimer's disease (AD) prompts that preventing or delaying the onset of AD should be a public health priority. Vitamin B supplements can lower the serum homocysteine (Hcy) level, but whether it can prevent cognitive decline or not remains unclear. We aimed to evaluate the preventive efficacy of vitamin B supplements on the cognitive decline of elderly adults. METHODS: We searched PubMed, Embase, The Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Scopus, Science Direct, PsycINFO from inception to December 1, 2019, and then updated the retrieved results on June 1, 2020. The randomized controlled trials (RCTs) which evaluated the efficacy of vitamin B in mild cognitive impairment (MCI) patients or elderly adults without cognitive impairment were selected. Standardized mean difference (SMD) or mean difference (MD) as well as their 95 % confidence interval (CI) were calculated by performing random effects models or fixed effects models. RESULTS: A total of 21 RCTs involving 7571 participants were included for meta-analysis. The forest plots showed that there is significant effect in global cognitive function (15 RCTs, SMD: 0.36; 95 % CI: 0.18 to 0.54, P < 0.01) and Hcy (11 RCTs, MD: -4.59; 95 %CI: -5.51 to -3.67, P < 0.01), but there is no effect in information processing speed (10 RCTs, SMD: 0.06; 95 % CI: -0.12 to 0.25, P = 0.49), episodic memory (15 RCTs, SMD: 0.10; 95 % CI: -0.04 to 0.25, P = 0.16), executive function (11 RCTs, SMD: -0.21; 95 % CI: -0.49 to 0.06, P = 0.13). The value of effect size and heterogeneity did not vary apparently when excluding the low-quality studies, so we could believe that the results of meta-analysis were robust. CONCLUSIONS:Vitamin B supplements might delay or maintain the cognitive decline of elderly adults. We can recommend that the vitamin B supplements should be considered as a preventive medication to MCI patients or elderly adults without cognitive impairment. More well-designed RCTs with large sample sizes were required to clarify the preventive efficacy in the future.
Authors: Simone J Eussen; Lisette C de Groot; Liesbeth W Joosten; Rubia J Bloo; Robert Clarke; Per M Ueland; Jörn Schneede; Henk J Blom; Willibrord H Hoefnagels; Wija A van Staveren Journal: Am J Clin Nutr Date: 2006-08 Impact factor: 7.045
Authors: Jennifer A McMahon; Timothy J Green; C Murray Skeaff; Robert G Knight; Jim I Mann; Sheila M Williams Journal: N Engl J Med Date: 2006-06-29 Impact factor: 91.245
Authors: Timothy Kwok; Jenny Lee; Ronald C Ma; Samuel Y Wong; Kenny Kung; Augustine Lam; C S Ho; Vivian Lee; John Harrison; Linda Lam Journal: Clin Nutr Date: 2016-10-27 Impact factor: 7.324
Authors: M Fioravanti; E Ferrario; M Massaia; G Cappa; G Rivolta; E Grossi; A E Buckley Journal: Arch Gerontol Geriatr Date: 1998 Jan-Feb Impact factor: 3.250
Authors: Anna Andrea Lauer; Heike Sabine Grimm; Birgit Apel; Nataliya Golobrodska; Lara Kruse; Elina Ratanski; Noemi Schulten; Laura Schwarze; Thomas Slawik; Saskia Sperlich; Antonia Vohla; Marcus Otto Walter Grimm Journal: Biomolecules Date: 2022-01-14